A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Chen, Shiuan, Ph.D. Laboratory

Laboratory of Shiuan Chen, Ph.D.
Breast Cancer Translational Research
Dr. Shiuan Chen was one of the three investigators who originally isolated the full-length human aromatase cDNA clones. Aromatase is an enzyme that converts androgen to estrogen. Aromatase inhibitors (AIs) are important drugs to treat estrogen-dependent breast cancer. Approximately 60% of premenopausal and 75% of postmenopausal breast cancer patients have estrogen-dependent carcinomas.
 
Since aromatase is the enzyme responsible for the synthesis of estrogen, and estrogen can have a major effect in the development of breast cancer, an abnormal expression of aromatase in breast cancer cells and/or surrounding adipose stromal cells may have a significant influence on breast tumor development and growth in cancer patients. Aromatase is expressed at higher levels in human breast cancer tissue than in normal breast tissue, as measured by various biochemical assays. During the last ten years, AIs have been demonstrated to be superior to tamoxifen for the treatment of hormonal dependent breast cancer. While this new generation of aromatase inhibitors is shown to be useful in the treatment of hormonal responsive breast cancer, resistance to such endocrine therapy still develops. Through collaboration with Yate-Ching Yuan, Ph.D., (Bioinformatics), we are carrying out gene expression array experiments on AI-responsive as well as resistant cell lines that have been generated in our laboratory. We plan to identify and functionally confirm the roles of genes involved in resistance.
 
It is hypothesized that these studies will produce valuable molecular information regarding the mechanisms of AI resistance, and the information will help design approaches to reduce resistance and improve the efficacy of AI treatments of breast cancer. Furthermore, our research has led to the identification of a HDAC inhibitor: LBH589 is a selective aromatase expression suppressor and a drug to inhibit the development of AI resistance. After reviewing the results generated from our preclinical studies, we have started working with Joanne Mortimer, M.D., George Somlo, M.D. and Thehang Luu, M.D., (Medical Oncology) in the design of new therapeutic approaches to treat AI resistant breast cancer. Hormone Diagram
 
We are also conducting research to determine how environmental chemicals modulate the activity and expression of aromatase in human tissue. Experiments are being conducted to provide a molecular and mechanistic basis as to how phytochemicals and organochlorine compounds affect estrogen biosynthesis (i.e., aromatase function) in women. Research from Dr. Chen's and other laboratories have revealed that ER, aromatase, and ERRα are key players in breast cancer promotion and in cancer recurrence following endocrine treatment. Furthermore, proof-of-concept studies have revealed that these proteins are targets of endocrine disruptors. Based on these observations, we hypothesize that environmental chemicals will play critical roles in modulating breast cancer through ER, aromatase, and ERRα. The goal of this research is to develop screening assays for identifying and testing chemicals with relevance to known and suspected causes of estrogen-dependent breast cancer. Our collaborators include Richard Yip, Ph.D. (High Throughput Screening Core), Charles Wang, Ph.D. (Functional Genomics Core), Yate-Ching Yuan, Ph.D. (Bioinformatics Core), Christina Teng, Ph.D. (National Institute of Environmental Health Sciences), and Sandra Finestone, Psy.D. (Hope Wellness Center, Costa Mesa, CA).
 
For more information on Dr. Chen, please click here.

Chemoprevention Research Program

Since the summer of 2004, Dr. Chen and 27 other investigators have initiated an effort to develop a chemoprevention research program at City of Hope. Through biweekly meetings, these Beckman researchers and clinicians exchange research information and ideas. Four research areas have recently been chosen to focus on. The immediate goal is to generate preliminary results in these new target areas that will lead to the development of multidiscipline translational chemoprevention research projects at our institution.
 
Our laboratory has found that grapes, mushrooms and pomegranate contain chemicals that can suppress aromatase activity. Therefore, a diet that includes grapes, mushrooms and pomegranate would be considered preventative against breast cancer. We are purifying and characterizing these natural anti-aromatase chemicals and evaluating their in vivo effects using animal experiments. The active chemicals in grapes have been found to be procyanidin dimers that are present at high concentrations in grape seeds. Melanie Palomares, M.D., (Population Sciences), Jeffrey Weitzel, M.D., (Clinical Cancer Genetics), Tim Synold, Pharm.D., (Experimental Therapeutics) and this laboratory have collaborated and initiated a grape seed extract clinical trial and a mushroom clinical trial based on the chemoprevention studies against breast cancer performed in our laboratory.
 
Furthermore, we have found that mushrooms contain chemicals that act as inhibitors of steroid 5-alpha reductase. Androgen plays a critical role in prostate cancer development. In the prostate, testosterone (an androgen) is converted to dihydrotestosterone (DHT), an androgen that is even more potent than testosterone. This conversion is catalyzed by the enzyme steroid 5-alpha reductase. An elevation of the steroid 5-alpha reductase activity in the prostate may cause benign prostate hyperplasia (a common problem in older men) and also promote the growth of prostate cancer. Animal experiments have been performed to evaluate the use of these phytochemicals as drugs in the prevention and/or treatment of prostate cancer. One clinical trial designed, based Dr. Chen's findings, is being carried out at City of Hope with Przemyslaw Twardowski, M.D. (Medical Oncology). A recent study in the Chen laboratory has revealed that the intake of mushrooms may reduce the incidence of metabolic diseases such as fatty liver and insulin resistance.
 
In addition, experiments have been carried out to show that blueberry contains phytochemicals that can suppress the proliferation and migration of triple negative breast cancer in cell culture and animals. Efforts are being made to initiate a blueberry clinical trial at City of Hope.
 

Lab Members

Hei (Jason) Chan, B.S.
Graduate Student
626-256-HOPE (4673), Ext. 63056
 
Zhike Chen, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 6506
 
Masaya Kai, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 60562
 
Noriko Kanaya, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 65062
 
Karineh Petrossian, M.S.
Graduate Student
626-256-HOPE (4673), Ext. 65062
 
Yuan-Zhong Wang, Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 6305
 
Cynthie Wong , Ph.D.
Post-doctoral Fellow
626-256-HOPE (4673), Ext. 63056
 
Dujin Zhou, Ph.D.
Associate Research Scientist
626-256-HOPE (4673), Ext. 64908
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • The burgeoning type 2 diabetes epidemic casts a pall over the health of America’s public. New research now shows the looming threat is getting worse. Much worse. A diabetes trends study published earlier this mongh in the Lancet Diabetes and Endocrinology by researchers at the federal Centers for Disease Contro...
  • An aspirin a day might help keep breast cancer away for some breast cancer survivors, a new study suggests. Obese women who have had breast cancer could cut their risk of a recurrence in half if they regularly take aspirin or other nonsteroidal anti-inflammatory drugs, called NSAIDs, report researchers from the...
  • Christine Crews isn’t only a fitness enthusiast, she’s also a personal trainer and fitness instructor. Being active defines her life. So when she was diagnosed with bladder cancer at age 30, she decided she absolutely couldn’t let the disease interfere with that lifestyle. And it didn’t. For t...
  • Cancer treatment and the cancer itself can cause changes in your sense of taste or smell. These side effects typically subside after treatment ends, but there are ways to help alleviate those bitter and metallic tastes in your mouth. Here are tips from the National Cancer Institute to help keeps tastes and food...
  • Immunotherapy — using one’s immune system to treat a disease — has been long lauded as the “magic bullet” of cancer treatments, one that can be more effective than the conventional therapies of surgery, radiation or chemotherapy. One specific type of immunotherapy, called adoptive T cell thera...
  • Today, when cancer spreads from its original site to other parts of the body, a process known as metastasis, patients face an uphill battle. Treatments are poorly effective, and cures are nearly impossible. Further, incidence rates for these types of cancers are increasing – particularly for cancers that have s...
  • Thanks to the California Institute for Regenerative Medicine (CIRM), high school students across the state gained valuable hands-on experience with stem cell research this summer. City of Hope hosted eight of those students. As part of the CIRM Creativity Awards program, the young scholars worked full time as m...
  • Radiation therapy can help cure many children facing Hodgkin lymphoma and other cancers. When the radiation is delivered to a girl’s chest, however, it can lead to a marked increase in breast cancer risk later in life. A recent multi-institutional study that included City of Hope’s Smita Bhatia, M.D., M.P.H., t...
  • A patient diagnosed with cancer – especially a rare, advanced or hard-to-treat cancer – needs specialized care from exceptionally skilled and highly trained experts. That kind of care saves lives, improves quality of life and keeps families whole. That kind of care is best found at comprehensive cancer centers ...
  • Appetite loss may be common during cancer treatment, lasting throughout your therapy or only occasionally, but it can be managed. Below are tips from the National Cancer Institute (NCI) that can help you keep your weight up and, in doing so, keep your body well-nourished. (See the end of this article for a deli...
  • Myelodysplasia, sometimes referred to as myelodysplastic syndrome or MDS, is a rare group of blood disorders caused by disrupted development of blood cells within the bone marrow, resulting in a decreased number of healthy blood cells. People diagnosed with the condition, considered a precancer, may be at great...
  • Twenty years ago, scientists discovered that a mutation in a gene now widely known as BRCA1 was linked to a sharply increased risk of breast cancer, paving the way for a new chapter in identifying women at risk of the disease and giving them options to potentially avoid an aggressive cancer. But experts have al...
  • The Eugene and Ruth Roberts Summer Student Academy at City of Hope turned 54 this year. Marking the occasion, the academy announced a new scholarship in honor of longtime director Paul Salvaterra, Ph.D. Salvaterra, a professor in City of Hope’s Department of Neurosciences, has led the summer student acade...
  • Stevee Rowe has a very personal connection to the research she’s conducting on neural stem cells: Her late father participated in a City of Hope clinical trial involving neural stem cells. Rowe — her full name is Alissa Stevee Rowe, but she prefers to use her middle name — will enter her senior year at the [...
  • Although multiple myeloma is classified as a blood cancer, patients with this disease often experience bone-related symptoms, too. This includes bone pain, frequent fractures and spots of low bone density or bone damage that show up during a skeletal scan. Here, Amrita Krishnan, M.D., director of City of Hope&#...